{"nctId":"NCT02486653","briefTitle":"Prevention of Post-operative Urinary Retention","startDateStruct":{"date":"2015-08","type":"ACTUAL"},"conditions":["Urinary Retention","Urinary Tract Infections"],"count":158,"armGroups":[{"label":"Tamsulosin","type":"EXPERIMENTAL","interventionNames":["Drug: Tamsulosin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tamsulosin","otherNames":["Flomax"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* English-speaking\n* Able to provide informed consent\n* Scheduled to undergo an elective, complex intra-abdominal operation with a planned postoperative inpatient stay of at least 1 night\n\nExclusion Criteria:\n\n* Less than age 18\n* Allergy or contraindication to tamsulosin\n* Serious sulfa allergy\n* Current use of alpha blocker (alfuzosin, doxazosin, prazosin, silodosin, terazosin, verapamil, tamsulosin) or oral alpha agonist (midodrine), or initiation of one of these medications during the intervention phase of the study will result in subject withdrawal from the study\n* Current warfarin use\n* Pre-existing indwelling urinary catheter, suprapubic catheter, or urostomy\n* End stage renal disease or dialysis-dependence\n* Sitting systolic blood pressure in the upper extremity of less than 100mm Hg at time of eligibility screening\n* Presence of orthostatic hypotension at the time of eligibility screening (orthostatic hypotension is defined as a drop in systolic blood pressure of 20mm Hg from sitting to standing, or drop in diastolic BP of 10 mm Hg from sitting to standing after 2-3 minutes of standing after being in a sitting position)\n* Anticipated inability to take oral medications on post-operative day #0\n* Anticipated requirement for indwelling urinary catheter beyond post-operative day #2\n* Non-English speaking\n* Pregnant or breast-feeding\n* Unwillingness to answer all 7 questions on the IPSS (International Prostate Symptom Score) survey\n* Lacking capacity to provide informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Need for Any Intermittent Catheterization Postoperatively as a Binary Outcome","description":"need for any intermittent catheterization after leaving the operating room or after initial indwelling urinary catheter (IUC) removal; subjects will be straight catheterized if the subject either 1) reports bladder discomfort, or 2) has a bladder scan for \\>500milliliters; or 3) has a post-void residual volume \\>500milliliters","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Need for Replacement of Indwelling Urinary Catheter as a Binary Outcome","description":"Need for replacement of an IUC after surgery or after initial removal of an IUC that was placed at the time of surgery; replacement of IUC is dictated by the institutional bladder management protocol after requiring the use of straight catheterization for 24 hours","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Time Until First Spontaneous Void","description":"time from IUC removal, last intermittent catheterization (if performed in the operating room or post-anesthesia care unit), or departure from the operating room (if no IUC placed intraoperatively) until first spontaneous void","classes":[]},{"type":"SECONDARY","title":"Total Number of Intermittent Catheterizations Required Per Subject","description":"total number of intermittent catheterizations required, as dictated by the institutional bladder management protocol","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"First Post-void Residual Urine Volume","description":"The post-void residual (PVR) urine volume as measured by bedside hand-held bladder scanning immediately following the first spontaneous void","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"218","spread":"167"},{"groupId":"OG001","value":"154","spread":"138"}]}]}]},{"type":"SECONDARY","title":"Discharge From Hospital With Indwelling Urinary Catheter","description":"Does the subject have a urinary catheter in place at the time of discharge from the hospital? This is a binary outcome measure of whether or not the subject is discharged from the hospital with an indwelling urinary catheter in place due to inadequate voiding function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Urinary Tract Infection (UTI)","description":"Either a culture-positive UTI prior to discharge from the hospital or subject self-reported clinician-diagnosed UTI occurring within 30 days of surgery","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Hospital Length of Stay in Days","description":"Collected after the participant is discharged from the hospital, total number of consecutive days (including day of surgery) until the participant is discharged from the hospital","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":"3.9"},{"groupId":"OG001","value":"6.0","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Experienced Adverse Events","description":"Adverse events, systematically collected. Summary results reported here, please refer to Adverse Events section of the results record for detailed reporting.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":76},"commonTop":["Dizziness","Hypotension","Renal and urinary disorders - Other, specify","Blurred vision","Dry skin"]}}}